Masaaki Goto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masaaki Goto has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Hideyuki Sakurai
Proton Medical Research Center, Department of Radiation Oncology University of Tsukuba Hospital Tsukuba Ibaraki Japan
5 shared publicationsToshiki Ishida
Proton Medical Research Center, Department of Radiation Oncology University of Tsukuba Hospital Tsukuba Ibaraki Japan
3 shared publications- Yoshio Yamashita
Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Saga University, Saga, Japan
3 shared publications - Atsushi Danjo
Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Saga University, Saga, Japan
2 shared publications - Kei Nakai
Department of Radiation Oncology, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan
2 shared publications Keiichiro Baba
Proton Medical Research Center, Department of Radiation Oncology University of Tsukuba Hospital Tsukuba Ibaraki Japan
2 shared publications
Latest Publications
- Open Access
Association of Chronological Age and Comorbidity Burden with Outcomes After Proton Beam Therapy for Hepatocellular Carcinoma
Background/Objectives: The prognostic relevance of chronological age versus comorbidity burden in patients with hepatocellular carcinoma (HCC) undergoing proton beam therapy (PBT) is unclear. This study evaluated whether comorbidity burden provides prognostic information beyond age. Methods: We retrospectively analyzed 269 patients with HCC treated with PBT between December 2009 and March 2015. Patients were classified as elderly (≥75 years, n = 105) or non-elderly (n = 164). Overall survival (OS), local control (LC), progression-free survival (PFS), and treatment-related adverse events were assessed. Comorbidity burden was evaluated using the Charlson Comorbidity Index (CCI). Multivariable Cox regression analyses were performed for OS and PFS. Results: The 3-year OS rates were 65.9% in the elderly group and 56.9% in the non-elderly group (p = 0.20), while the corresponding LC rates were 86.7% and 90.5% (p = 0.24) and PFS rates were 30.3% and 29.9% (p = 0.81), respectively. In multivariable analyses, age ≥ 75 years was not significantly associated with OS (HR, 1.25; 95% CI, 0.89–1.74; p = 0.198) or PFS (HR, 1.15; 95% CI, 0.86–1.54; p = 0.331). In contrast, CCI ≥ 3, compared with CCI 0, was independently associated with poorer OS (HR, 3.31; 95% CI, 1.54–7.15; p = 0.002), while its association with PFS did not reach statistical significance (HR, 1.87; 95% CI, 0.98–3.58; p = 0.057). No significant age × CCI interaction was observed for OS or PFS. Conclusions: Chronological age was not independently associated with OS or PFS in patients with HCC treated with PBT, whereas a high comorbidity burden was independently associated with poorer OS. These findings suggest that comorbidity burden should be considered in addition to chronological age when estimating prognosis after PBT.
Open AccessAssociation of Chronological Age and Comorbidity Burden with Outcomes After Proton Beam Therapy for Hepatocellular Carcinoma
Background/Objectives: The prognostic relevance of chronological age versus comorbidity burden in patients with hepatocellular carcinoma (HCC) undergoing proton beam therapy (PBT) is unclear. This study evaluated whether comorbidity burden provides prognostic information beyond age. Methods: We retrospectively analyzed 269 patients with HCC treated with PBT between December 2009 and March 2015. Patients were classified as elderly (≥75 years, n = 105) or non-elderly (n = 164). Overall survival (OS), local control (LC), progression-free survival (PFS), and treatment-related adverse events were assessed. Comorbidity burden was evaluated using the Charlson Comorbidity Index (CCI). Multivariable Cox regression analyses were performed for OS and PFS. Results: The 3-year OS rates were 65.9% in the elderly group and 56.9% in the non-elderly group (p = 0.20), while the corresponding LC rates were 86.7% and 90.5% (p = 0.24) and PFS rates were 30.3% and 29.9% (p = 0.81), respectively. In multivariable analyses, age ≥ 75 years was not significantly associated with OS (HR, 1.25; 95% CI, 0.89–1.74; p = 0.198) or PFS (HR, 1.15; 95% CI, 0.86–1.54; p = 0.331). In contrast, CCI ≥ 3, compared with CCI 0, was independently associated with poorer OS (HR, 3.31; 95% CI, 1.54–7.15; p = 0.002), while its association with PFS did not reach statistical significance (HR, 1.87; 95% CI, 0.98–3.58; p = 0.057). No significant age × CCI interaction was observed for OS or PFS. Conclusions: Chronological age was not independently associated with OS or PFS in patients with HCC treated with PBT, whereas a high comorbidity burden was independently associated with poorer OS. These findings suggest that comorbidity burden should be considered in addition to chronological age when estimating prognosis after PBT.
- Open Access
- 31 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9) , e72242
Prognostic Impact of Arterial Phase Hyperenhancement After Proton Beam Therapy for Untreated Solitary Hepatocellular Carcinoma
Purpose: To evaluate the significance of persistent arterial‐phase hyperenhancement (APHE) on contrast‐enhanced CT/MRI at 6 and 12 months after proton beam therapy (PBT) for hepatocellular carcinoma (HCC). Methods: We retrospectively analyzed 108 patients with solitary HCC without vascular invasion who underwent definitive PBT as initial treatment between January 2008 and December 2020. APHE was assessed on contrast‐enhanced CT/MRI at approximately 6 and 12 months. Overall survival (OS), local control (LC), and progression‐free survival (PFS) were estimated using the Kaplan–Meier method. Associations between APHE and outcomes were evaluated using landmark analyses and Cox models. Results: The median follow‐up time was 4.64 years. APHE assessment was available in 87 patients at 6 months and 89 patients at 12 months; APHE was observed in 28 (32.2%) and 26 (29.2%), respectively. At the 6‐month landmark, APHE was associated with worse subsequent OS and PFS, whereas LC did not differ significantly. At the 12‐month landmark, APHE was associated with worse subsequent LC and PFS and borderline worse OS. The 3‐year LC and PFS rates from the 12‐month landmark were 69.1% and 25.3% in patients with APHE versus 89.6% and 54.3% in those without APHE (LC: p = 0.015; PFS: p = 0.025). However, after adjustment for clinical and treatment‐related factors, APHE status was not independently associated with OS, LC, or PFS in the multivariate landmark analyses. Conclusion: Persistent intratumoral APHE at 12 months after PBT was associated with an increased subsequent risk of local failure in landmark analysis, but was not an independent prognostic factor. Persistent APHE may warrant careful imaging follow‐up and clinical reassessment but should not be regarded as definitive evidence of viable tumor.
- 31 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9) , e72242
Open AccessPrognostic Impact of Arterial Phase Hyperenhancement After Proton Beam Therapy for Untreated Solitary Hepatocellular Carcinoma
Purpose: To evaluate the significance of persistent arterial‐phase hyperenhancement (APHE) on contrast‐enhanced CT/MRI at 6 and 12 months after proton beam therapy (PBT) for hepatocellular carcinoma (HCC). Methods: We retrospectively analyzed 108 patients with solitary HCC without vascular invasion who underwent definitive PBT as initial treatment between January 2008 and December 2020. APHE was assessed on contrast‐enhanced CT/MRI at approximately 6 and 12 months. Overall survival (OS), local control (LC), and progression‐free survival (PFS) were estimated using the Kaplan–Meier method. Associations between APHE and outcomes were evaluated using landmark analyses and Cox models. Results: The median follow‐up time was 4.64 years. APHE assessment was available in 87 patients at 6 months and 89 patients at 12 months; APHE was observed in 28 (32.2%) and 26 (29.2%), respectively. At the 6‐month landmark, APHE was associated with worse subsequent OS and PFS, whereas LC did not differ significantly. At the 12‐month landmark, APHE was associated with worse subsequent LC and PFS and borderline worse OS. The 3‐year LC and PFS rates from the 12‐month landmark were 69.1% and 25.3% in patients with APHE versus 89.6% and 54.3% in those without APHE (LC: p = 0.015; PFS: p = 0.025). However, after adjustment for clinical and treatment‐related factors, APHE status was not independently associated with OS, LC, or PFS in the multivariate landmark analyses. Conclusion: Persistent intratumoral APHE at 12 months after PBT was associated with an increased subsequent risk of local failure in landmark analysis, but was not an independent prognostic factor. Persistent APHE may warrant careful imaging follow‐up and clinical reassessment but should not be regarded as definitive evidence of viable tumor.
- Open Access
- 15 June 2026
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 44 (9) , 1702-1703
In situ pulmonary artery thrombosis after proton beam therapy
- 15 June 2026
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 44 (9) , 1702-1703
Open AccessIn situ pulmonary artery thrombosis after proton beam therapy
- Open Access
- 20 February 2026
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 43 (2)
Clinical utility of the ESTRO–EORTC classification in oligometastatic disease treated with stereotactic body radiotherapy: a single-institution retrospective study
The online version contains supplementary material available at 10.1007/s10585-026-10398-x.
- 20 February 2026
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 43 (2)
Open AccessClinical utility of the ESTRO–EORTC classification in oligometastatic disease treated with stereotactic body radiotherapy: a single-institution retrospective study
The online version contains supplementary material available at 10.1007/s10585-026-10398-x.
- Open Access
- 7 March 2025
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 66 (2) , 144-156
Development of a deep learning-based model to evaluate changes during radiotherapy using cervical cancer digital pathology
This study aims to create a deep learning-based classification model for cervical cancer biopsy before and during radiotherapy, visualize the results on whole slide images (WSIs), and explore the clinical significance of obtained features. This study included 95 patients with cervical cancer who received radiotherapy between April 2013 and December 2020. Hematoxylin–eosin stained biopsies were digitized to WSIs and divided into small tiles. Our model adopted the feature extractor of DenseNet121 and the classifier of the support vector machine. About 12 400 tiles were used for training the model and 6000 tiles for testing. The model performance was assessed on a per-tile and per-WSI basis. The resultant probability was defined as radiotherapy status probability (RSP) and its color map was visualized on WSIs. Survival analysis was performed to examine the clinical significance of the RSP. In the test set, the trained model had an area under the receiver operating characteristic curve of 0.76 per-tile and 0.95 per-WSI. In visualization, the model focused on viable tumor components and stroma in tumor biopsies. While survival analysis failed to show the prognostic impact of RSP during treatment, cases with low RSP at diagnosis had prolonged overall survival compared to those with high RSP (P = 0.045). In conclusion, we successfully developed a model to classify biopsies before and during radiotherapy and visualized the result on slide images. Low RSP cases before treatment had a better prognosis, suggesting that tumor morphologic features obtained using the model may be useful for predicting prognosis.
- 7 March 2025
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 66 (2) , 144-156
Open AccessDevelopment of a deep learning-based model to evaluate changes during radiotherapy using cervical cancer digital pathology
This study aims to create a deep learning-based classification model for cervical cancer biopsy before and during radiotherapy, visualize the results on whole slide images (WSIs), and explore the clinical significance of obtained features. This study included 95 patients with cervical cancer who received radiotherapy between April 2013 and December 2020. Hematoxylin–eosin stained biopsies were digitized to WSIs and divided into small tiles. Our model adopted the feature extractor of DenseNet121 and the classifier of the support vector machine. About 12 400 tiles were used for training the model and 6000 tiles for testing. The model performance was assessed on a per-tile and per-WSI basis. The resultant probability was defined as radiotherapy status probability (RSP) and its color map was visualized on WSIs. Survival analysis was performed to examine the clinical significance of the RSP. In the test set, the trained model had an area under the receiver operating characteristic curve of 0.76 per-tile and 0.95 per-WSI. In visualization, the model focused on viable tumor components and stroma in tumor biopsies. While survival analysis failed to show the prognostic impact of RSP during treatment, cases with low RSP at diagnosis had prolonged overall survival compared to those with high RSP (P = 0.045). In conclusion, we successfully developed a model to classify biopsies before and during radiotherapy and visualized the result on slide images. Low RSP cases before treatment had a better prognosis, suggesting that tumor morphologic features obtained using the model may be useful for predicting prognosis.
- Open Access
- 21 January 2022
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 63 (2) , 314-318
A novel method for skin marking in radiotherapy: first clinical use of temporary organic tattoo seal
An oil-based pen is widely used as a skin marker for identification of the isocenter and computed tomography (CT)-coordinate origin during radiotherapy. However, use of this pen has some disadvantages, including color loss and color migration. To address these problems, we have developed use of a temporary fashion tattoo (Inkbox) for skin marking. The utility and feasibility of Inkbox as an alternative to an oil-based pen were evaluated in this study. The study included patients from two centers who required skin marking for radiotherapy performed between December 2020 and March 2021. Skin markings were made with an oil-based pen or with Inkbox. The durability was recorded during daily irradiation. Skin markings with Inkbox were made in 32 patients. The total number of skin markings was 94: 64 with Inkbox and 30 with an oil-based pen. A questionnaire survey to evaluate each method was conducted among patients after radiotherapy. The median durations of marking were 16 and 4 days with Inkbox and an oil-based pen, respectively (p-value < 0.001). The survey showed that Inkbox had less impact on the daily lives of patients, including reduced color migration to clothes and less concern about disappearance of the marking. There were no adverse cutaneous side effects with Inkbox. The duration of marking with Inkbox is about 16 days, with little impact on daily life. These findings suggest that Inkbox is a potentially useful method of skin marking in radiotherapy.
- 21 January 2022
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 63 (2) , 314-318
Open AccessA novel method for skin marking in radiotherapy: first clinical use of temporary organic tattoo seal
An oil-based pen is widely used as a skin marker for identification of the isocenter and computed tomography (CT)-coordinate origin during radiotherapy. However, use of this pen has some disadvantages, including color loss and color migration. To address these problems, we have developed use of a temporary fashion tattoo (Inkbox) for skin marking. The utility and feasibility of Inkbox as an alternative to an oil-based pen were evaluated in this study. The study included patients from two centers who required skin marking for radiotherapy performed between December 2020 and March 2021. Skin markings were made with an oil-based pen or with Inkbox. The durability was recorded during daily irradiation. Skin markings with Inkbox were made in 32 patients. The total number of skin markings was 94: 64 with Inkbox and 30 with an oil-based pen. A questionnaire survey to evaluate each method was conducted among patients after radiotherapy. The median durations of marking were 16 and 4 days with Inkbox and an oil-based pen, respectively (p-value < 0.001). The survey showed that Inkbox had less impact on the daily lives of patients, including reduced color migration to clothes and less concern about disappearance of the marking. There were no adverse cutaneous side effects with Inkbox. The duration of marking with Inkbox is about 16 days, with little impact on daily life. These findings suggest that Inkbox is a potentially useful method of skin marking in radiotherapy.
- 1 October 2015
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 44, e51
Histological evaluation of the bone healing by osteotomy with ultrasonic osteotomy devices
- 1 October 2015
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 44, e51
Histological evaluation of the bone healing by osteotomy with ultrasonic osteotomy devices
- Open Access
- 1 January 2015
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 41 (4) , 432-436
Three oral cancer cases treated using dental implants provided by public health insurance
- 1 January 2015
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 41 (4) , 432-436
Open AccessThree oral cancer cases treated using dental implants provided by public health insurance
- 1 August 2011
- Published by IOP Publishing in Japanese Journal of Applied Physics
- Vol. 50 (8S1) , 08JF04
Redox Characteristics of Thiol Compounds Using Radicals Produced by Water Vapor Radio Frequency Discharge
The redox reaction between cystein and cystine is observed using radicals produced in water vapor plasma for the control of plant growth. Cystein is oxidized to cystine using the OH radical in the higher-pressure regime and cystine is reduced to cystein by the H radical generated in the lower-pressure regime. Also, the oxidative stress reaction of plants is observed when water vapor plasma is irradiated onto seeds of plants such as radish sprouts. The mechanism of the control of plant growth is explained by the change in thiol compound quantity of the plant cells induced by the radical reaction.
- 1 August 2011
- Published by IOP Publishing in Japanese Journal of Applied Physics
- Vol. 50 (8S1) , 08JF04
Redox Characteristics of Thiol Compounds Using Radicals Produced by Water Vapor Radio Frequency Discharge
The redox reaction between cystein and cystine is observed using radicals produced in water vapor plasma for the control of plant growth. Cystein is oxidized to cystine using the OH radical in the higher-pressure regime and cystine is reduced to cystein by the H radical generated in the lower-pressure regime. Also, the oxidative stress reaction of plants is observed when water vapor plasma is irradiated onto seeds of plants such as radish sprouts. The mechanism of the control of plant growth is explained by the change in thiol compound quantity of the plant cells induced by the radical reaction.
- Open Access
- 1 January 2004
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 50 (12) , 789-792
Use of an Implant-Finder to locate metallic foreign bodies in the oral and maxillary region
- 1 January 2004
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 50 (12) , 789-792
Open AccessUse of an Implant-Finder to locate metallic foreign bodies in the oral and maxillary region